https://www.iebrain.com –
AI is regarded as a tool to uncover not only new molecules but also new targets. Deep neural networks' ability to construct ontologies from multimodal data (e.g., "omics" data) is thought to be one of the most disruptive areas for AI in drug development, along with data mining from unstructured data such as text (using natural language processing, NLP).
Ingenious e-Brain Solutions forecasts a considerable trend for “AI democratization” where various machine learning/deep learning technologies become available in pre-trained, pre-configured “off-the-shelf” formats, or relatively ready-to-use formats — via cloud-based models, frameworks, and drag-and-drop AI-pipeline building platforms (for example, KNIME). Companies such as Google, Tencent, Nvidia, Microsoft, and others are expanding into the healthcare space by not only providing specialized services and tools to pharma counterparties but also investing directly in biotech start-ups and larger companies, establishing their own centers of excellence and commercial subsidiaries with a focus on Life Sciences.
Read more »